NSI-189
|
- $57.2 - $2691.1
- Product name: NSI-189
- CAS: 1270138-40-3
- MF: C22H30N4O
- MW: 366.5
- EINECS:1592732-453-0
- MDL Number:MFCD26959792
- Synonyms:NSI-189;(4-BENZYLPIPERAZIN-1-YL)-[2-(3-METHYLBUTYLAMINO)PYRIDIN-3-YL]METHANONE;(4-BENZYLPIPERAZIN-1-YL)(2-(ISOPENTYLAMINO)PYRIDIN-3-YL)METHANONE;[2-[(3-Methylbutyl)amino]-3-pyridinyl][4-(phenylmethyl)-1-piperazinyl]methanone;[2-[(3-Methylbutyl)amino]-3-pyridinyl][4-(phenylmethyl)-1-piperazinyl]methanone NSI189;NSI-189 [2-[(3-Methylbutyl)amino]-3-pyridinyl][4-(phenylmethyl)-1-piperazinyl]methanone;NSI-189, >=98%;(4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]
22 prices
Selected condition：
Brand
- AK Scientific
- American Custom Chemicals Corporation
- ApexBio Technology
- Biorbyt Ltd
- Cayman Chemical
- Chemenu
- Crysdot
- DC Chemicals
- TRC
Package
- 1mg
- 5mg
- 10mg
- 50mg
- 100mg
- 250mg
- 1g
- 1000mg
- 5g
- ManufacturerAK Scientific
- Product numberJ10998
- Product descriptionNIS-189
- Packaging5mg
- Price$57.2
- Updated2021-12-16
- Buy
- ManufacturerAK Scientific
- Product numberJ53294
- Product description(4-Benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone
- Packaging5g
- Price$560
- Updated2021-12-16
- Buy
- ManufacturerAmerican Custom Chemicals Corporation
- Product numberAPI0027463
- Product description(4-BENZYLPIPERAZIN-1-YL)(2-(ISOPENTYLAMINO)PYRIDIN-3-YL)METHANONE 95.00%
- Packaging5MG
- Price$500.46
- Updated2021-12-16
- Buy
- ManufacturerApexBio Technology
- Product numberB1150
- Product descriptionNSI-189
- Packaging5mg
- Price$118
- Updated2021-12-16
- Buy
- ManufacturerApexBio Technology
- Product numberB1150
- Product descriptionNSI-189
- Packaging10mg
- Price$198
- Updated2021-12-16
- Buy
- ManufacturerApexBio Technology
- Product numberB1150
- Product descriptionNSI-189
- Packaging50mg
- Price$693
- Updated2021-12-16
- Buy
- ManufacturerApexBio Technology
- Product numberB1150
- Product descriptionNSI-189
- Packaging100mg
- Price$1331
- Updated2021-12-16
- Buy
- ManufacturerBiorbyt Ltd
- Product numberorb181029
- Product descriptionNSI-189 >98%
- Packaging100mg
- Price$690.2
- Updated2021-12-16
- Buy
- ManufacturerBiorbyt Ltd
- Product numberorb181029
- Product descriptionNSI-189 >98%
- Packaging250mg
- Price$1356.6
- Updated2021-12-16
- Buy
- ManufacturerBiorbyt Ltd
- Product numberorb181029
- Product descriptionNSI-189 >98%
- Packaging1000mg
- Price$2691.1
- Updated2021-12-16
- Buy
- ManufacturerCayman Chemical
- Product number26166
- Product descriptionNSI-189
- Packaging1mg
- Price$81
- Updated2024-03-01
- Buy
- ManufacturerCayman Chemical
- Product number26166
- Product descriptionNSI-189
- Packaging5mg
- Price$356
- Updated2024-03-01
- Buy
- ManufacturerChemenu
- Product numberCM169983
- Product description(4-Benzylpiperazin-1-yl)(2-(isopentylamino)pyridin-3-yl)methanone 98%
- Packaging1g
- Price$561
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD31004030
- Product descriptionNSI-189 98+%
- Packaging50mg
- Price$100
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD31004030
- Product descriptionNSI-189 98+%
- Packaging100mg
- Price$170
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD31004030
- Product descriptionNSI-189 98+%
- Packaging250mg
- Price$325
- Updated2021-12-16
- Buy
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|
| AK Scientific | J10998 | NIS-189 | 5mg | $57.2 | 2021-12-16 | Buy |
| AK Scientific | J53294 | (4-Benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone | 5g | $560 | 2021-12-16 | Buy |
| American Custom Chemicals Corporation | API0027463 | (4-BENZYLPIPERAZIN-1-YL)(2-(ISOPENTYLAMINO)PYRIDIN-3-YL)METHANONE 95.00% | 5MG | $500.46 | 2021-12-16 | Buy |
| ApexBio Technology | B1150 | NSI-189 | 5mg | $118 | 2021-12-16 | Buy |
| ApexBio Technology | B1150 | NSI-189 | 10mg | $198 | 2021-12-16 | Buy |
| ApexBio Technology | B1150 | NSI-189 | 50mg | $693 | 2021-12-16 | Buy |
| ApexBio Technology | B1150 | NSI-189 | 100mg | $1331 | 2021-12-16 | Buy |
| Biorbyt Ltd | orb181029 | NSI-189 >98% | 100mg | $690.2 | 2021-12-16 | Buy |
| Biorbyt Ltd | orb181029 | NSI-189 >98% | 250mg | $1356.6 | 2021-12-16 | Buy |
| Biorbyt Ltd | orb181029 | NSI-189 >98% | 1000mg | $2691.1 | 2021-12-16 | Buy |
| Cayman Chemical | 26166 | NSI-189 | 1mg | $81 | 2024-03-01 | Buy |
| Cayman Chemical | 26166 | NSI-189 | 5mg | $356 | 2024-03-01 | Buy |
| Chemenu | CM169983 | (4-Benzylpiperazin-1-yl)(2-(isopentylamino)pyridin-3-yl)methanone 98% | 1g | $561 | 2021-12-16 | Buy |
| Crysdot | CD31004030 | NSI-189 98+% | 50mg | $100 | 2021-12-16 | Buy |
| Crysdot | CD31004030 | NSI-189 98+% | 100mg | $170 | 2021-12-16 | Buy |
| Crysdot | CD31004030 | NSI-189 98+% | 250mg | $325 | 2021-12-16 | Buy |
Properties
Boiling point :534.7±50.0 °C(Predicted)
Density :1.134±0.06 g/cm3(Predicted)
storage temp. :-20°C
solubility :Soluble in DMSO
pka :6.18±0.10(Predicted)
form :A crystalline solid
λmax :254 nm
InChI :InChI=1S/C22H30N4O/c1-18(2)10-12-24-21-20(9-6-11-23-21)22(27)26-15-13-25(14-16-26)17-19-7-4-3-5-8-19/h3-9,11,18H,10,12-17H2,1-2H3,(H,23,24)
InChIKey :DYTOQURYRYYNOR-UHFFFAOYSA-N
SMILES :C(C1=CC=CN=C1NCCC(C)C)(N1CCN(CC2=CC=CC=C2)CC1)=O
Density :1.134±0.06 g/cm3(Predicted)
storage temp. :-20°C
solubility :Soluble in DMSO
pka :6.18±0.10(Predicted)
form :A crystalline solid
λmax :254 nm
InChI :InChI=1S/C22H30N4O/c1-18(2)10-12-24-21-20(9-6-11-23-21)22(27)26-15-13-25(14-16-26)17-19-7-4-3-5-8-19/h3-9,11,18H,10,12-17H2,1-2H3,(H,23,24)
InChIKey :DYTOQURYRYYNOR-UHFFFAOYSA-N
SMILES :C(C1=CC=CN=C1NCCC(C)C)(N1CCN(CC2=CC=CC=C2)CC1)=O
Safety Information
| Symbol(GHS): |
|
||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal word: | Warning | ||||||||||||||
| Hazard statements: |
|
||||||||||||||
| Precautionary statements: |
|
Description
NSI-189 is an investigational drug being developed by Neuralstem Inc., a biopharmaceutical company. NSI-189 is a small molecule in clinical development for major depressive disorder (MDD) and in preclinical development for Angelman syndrome, irradiation-induced cognitive impairment, Type 1 and Type 2 diabetes, and stroke. NSI-189 was studied in phase I and II clinical trials for the treatment of major depressive disorder. As of July 2017, NSI-189 has failed to meet effectiveness outcomes for depression in phase II trials.Suppliers and manufacturers
Jiangsu shring Biopharma Co., Ltd.
